Biocon Files IND For Oral Insulin In U.S.; Launch In India Likely In 2011
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Amidst a row over the safety and absorption profile of inhaled insulins, Biocon - which steadily advanced its orally-delivered insulin IN-105 into Phase III trials in India - has now filed an investigational new drug application with U.S. FDA